## **ORIGINAL CONTRIBUTION**



# **Intakes of long‑chain omega‑3 polyunsaturated fatty acids and non‑fried fsh in relation to incidence of chronic kidney disease in young adults: a 25‑year follow‑up**

**Inwhee Park1,2 · Pengcheng Xun1 · Cari Lewis Tsinovoi<sup>1</sup> · Philip Klemmer3 · Kiang Liu4 · Ka He1**

Received: 27 July 2018 / Accepted: 4 June 2019 / Published online: 7 June 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019

## **Abstract**

**Purpose** The prevalence of chronic kidney disease (CKD) is increasing rapidly in many countries and has become a major public health concern. Although intakes of long-chain omega-3 polyunsaturated fatty acids (LCω3PUFA) and its food source—fish—may have renal protective effects, little is known about the longitudinal association between these dietary factors and CKD incidence.

**Methods** A total of 4133 healthy individuals of black and white race aged 18–30 at baseline (1985–1986) from the Coronary Artery Risk Development in Young Adults study were enrolled and followed up over 25 years. LCω3PUFA and fsh intake were assessed by an interview-based dietary history questionnaire at baseline, year 7 (1992–1993) and 20 (2005–2006).

**Results** Four hundred and eighty-nine incident cases of CKD were identifed. After adjustment for potential confounders, LCω3PUFA intake was inversely associated with CKD incidence [HR = 0.73 (95% CI 0.60–0.89),  $P = 0.002$ , with one standard division (0.19 g/day) increment in LCω3PUFA]. This inverse association was persisted among females [0.64 (95% CI 0.48, 0.84;  $P = 0.002$ , but not males ( $P_{\text{interaction}} = 0.070$ ). A marginal significant inverse association was also found between non-fried fsh consumption and CKD incidence (HR=0.86, 95% CI 0.73, 1.01; *P*=0.073).

**Conclusions** Dietary LCω3PUFA intake was inversely associated with incidence of CKD among American young adults over 25 years of follow-up. The suggestive evidence of the inverse association between non-fried fsh consumption with CKD incidence needs further confrmation.

**Keywords** Chronic kidney disease · Proteinuria · Fish · Long-chain omega-3 polyunsaturated fatty acids



 $\boxtimes$  Ka He kahe@indiana.edu

- <sup>1</sup> Department of Epidemiology and Biostatistics, School of Public Health-Bloomington, Indiana University, 1025 E. 7th Street, Bloomington, IN 47405, USA
- <sup>2</sup> Department of Nephrology, School of Medicine, Ajou University, Suwon, Gyeonggi-do, Republic of Korea
- <sup>3</sup> Division of Nephrology and Hypertension, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
- <sup>4</sup> Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA



## **Introduction**

The global prevalence of chronic kidney disease (CKD) from 1999 to 2014 was around 11%, and CKD is an independent risk factor for cardiovascular morbidity and decreased quality of life [\[1](#page-6-0), [2](#page-6-1)]. Moreover, the prevalence is increasing rapidly in many countries and has become a major public health concern [[2](#page-6-1)–[5\]](#page-6-2). Because the fnal common pathway of chronic kidney damage often involves inflammation and fibrosis [[2\]](#page-6-1), intake of long-chain omega-3 polyunsaturated fatty acids (LCω3PUFA) via fsh oil supplements or non-fried fsh is considered benefcial, since they can down-regulate pro-infammatory cytokine production and oxidative stress, and express endothelial leukocyte adhesion molecules, thereby protecting kidney function [[6,](#page-6-3) [7\]](#page-6-4). To date, numerous studies have reported inverse associations of LCω3PUFA intake with cardiovascular diseases [[8\]](#page-6-5), hypertension [\[9\]](#page-6-6), and endothelial function [[10](#page-6-7)], all of which can increase risk of CKD [[11](#page-6-8)]. In addition, fsh oil is often prescribed in patients with IgA nephropathy [\[12\]](#page-6-9). However, some studies have shown no or at most a weak preventive efect on cardiovascular outcomes [[13](#page-6-10)–[15\]](#page-7-0).

Fish is enriched in LCω3PUFA species that include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [[16](#page-7-1)]. Despite the benefts which these fatty acids provide, fsh consumption may come with the potential for harm from contaminants such as mercury  $(Hg)$  [[16\]](#page-7-1). However, fsh is also a dietary source of selenium (Se) that can increase Hg elimination and ameliorate its toxic efects [\[17,](#page-7-2) [18](#page-7-3)]. Thus, it is important to consider both the benefts and risks of consuming fsh as routes of exposure to LCω3PUFA, Se, and Hg [[9\]](#page-6-6).

Few epidemiological studies have examined the putative association between fsh oil and a decline in glomerular fltration rate (GFR) [[6,](#page-6-3) [19,](#page-7-4) [20](#page-7-5)] and the association between fsh oil and albuminuria in the general population  $[21]$  $[21]$ . Two studies have shown that fish oil consumption was associated with a reduced likelihood of CKD. A cross-sectional study reported that dietary intake of LCω3PUFA and fish was inversely associated with risk of prevalent CKD [\[20\]](#page-7-5). An Italian populationbased cohort study of 931 adults aged  $\geq$  65 years showed that polyunsaturated fatty acid levels at enrollment were inversely associated with risk of developing reduced creatinine clearance during a 3-year follow-up [[19](#page-7-4)]. However, whether the fndings can be generalized to younger individuals with a long observational period is uncertain. Conversely, a study that examined the association between fish consumption and nephropathy in American Indians found no association between fsh consumption and risk of nephropathy [\[21\]](#page-7-6). However, fsh items consumed were

predominantly deep-fried in the study. Because of the gap in knowledge about the longitudinal association of intakes of LCω3PUFA and fsh with incidence of CKD, we undertook the present analysis using data from a large cohort of young adults participating in the Coronary Artery Risk Development in Young Adults (CARDIA) study.

## **Materials and methods**

#### **Design and participants**

The CARDIA study is an ongoing, multicenter, prospective cohort study of the development and determinants of cardiovascular risk factors in young adults aged 18–30 years at recruitment. Details of study design have been published elsewhere [\[22](#page-7-7)]. In brief, 5114 male and female participants of both black and white races were recruited in 1985 and 1986 (Y0) in four cities in the United States (Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA). The cohort was designed to be balanced by age, sex, race, and education. The follow-up examinations were conducted in 1987–1988 (Y2), 1990–1991 (Y5), 1992–1993 (Y7), 1995–1996 (Y10), 2000–2001 (Y15), 2005–2006 (Y20), and 2010–2011 (Y25). Retention rate of the surviving cohort in each follow-up was 90.4, 85.1, 79.9, 77.2, 71.8, 69.3, and 68.4%, respectively.

We excluded participants who reported an implausible total energy intake  $(< 800$  or  $> 8000$  kcal/day for males, and  $< 600$  or  $> 6000$  kcal/day for females) ( $n = 30$ ), with missing data on exposure variables at all diet assessments  $(n=4)$ and smoking status ( $n=54$ ), with CKD at baseline ( $n=6$ ), and participants without follow-up information for defning incidence of CKD  $(n=664)$ . To be conservative, we also excluded females who were pregnant at any examination (*n*=223). The remaining 4133 participants were included in the main analysis. Of these, 3690 participants with toenail Se and Hg available were included in the analyses of the efect modifcation of Se and Hg on the associations of interest. A written informed consent form was obtained from all participants. Supplemental Fig. 1 in the appendix shows the enrollment fow. The study design, data collection, and analyses were approved by the institutional review boards of the participating centers.

## **Ascertainment of fsh consumption and LCω3PUFA intake**

The CARDIA Diet History questionnaire is an intervieweradministered quantitative food-frequency questionnaire designed to assess habitual eating patterns. The validity and reproducibility of CARDIA food-frequency questionnaire have been described in the previous studies [[23,](#page-7-8) [24](#page-7-9)]. The correlation coefficients for logarithmically transformed nutrient values and energy-adjusted nutrient values from two dietary histories are 0.50–0.80 for whites and 0.30–0.70 for blacks [[24\]](#page-7-9). Briefy, diet assessment was conducted three times at Y0, Y7, and Y20. Participants were asked to recall their usual dietary intakes using the previous 30 days as the time frame. Daily intake of each food or beverage group was calculated as the sum of the number of servings consumed per day. Fish consumption was categorized into fried and non-fried fsh, recognizing that the health impact may be infuenced by the preparation method [\[25\]](#page-7-10). Because of the skewed and narrow distribution of fried fsh consumption, we did not use fried fsh as an exposure separately, but adjusted for fried fsh intake when examining the association between non-fried fsh intake and incidence of CKD. Nutrient intake was estimated using an adaptively updated nutrient database version 36 (Nutrition Data System for Research 2005 from the Nutrition Coordinating Center at the University of Minnesota, Minneapolis, MN). In this study, LCω3PUFA intake was defned as the sum of DHA, EPA, and docosapentaenoic acid from all dietary sources. Because of the relatively small amount and the narrow distribution, docosapentaenoic acid was not analyzed as a separate exposure.

#### **Ascertainment of CKD**

We defined CKD as an estimated GFR (eGFR)  $<$  60 mL/ min per 1.73 m<sup>2</sup> or albuminuria > 30 mg/g (urine albumin/ creatinine) [[2\]](#page-6-1). eGFR was estimated at Y0, Y10, Y15, Y20, and Y25 using the CKD-EPI (epidemiology collaboration) Creatinine Equation [\[26](#page-7-11)]. Albuminuria was determined from a single, untimed (spot) urine sample collected at Y10, Y15, Y20, and Y25 examinations. Urine albumin concentrations were measured using a nephelometric procedure with a specifc anti-albumin monoclonal antibody. Between study years 0 and 20, creatinine was measured using a modifedrate Jafe method and standardized to NIST standards. In Y25 examination, creatinine was measured using the Roche enzymatic method and standardized to NIST standards. Urine albumin–creatinine ratios were standardized to sex and race and expressed in milligrams per gram of creatinine [\[27\]](#page-7-12).

#### **Ascertainment of toenail se and Hg**

Details of assessment have been described previously [\[9](#page-6-6)]. Briefy, Se and Hg levels were analyzed by instrumental neutron-activation analysis at the University of Missouri Research Reactor. The average coefficient of variation in duplicate toenail sub-samples was 2.5% for Se and 6.8% for Hg. The toenail concentrations of Se or Hg were suggested to be useful biomarkers of exposure in which a single sample

was assumed to represent long-term exposure, since toenail clippings refect 9–12 months of exposure [\[28](#page-7-13)[–30](#page-7-14)].

## **Ascertainment of covariates**

Age, race, sex, smoking status, and hyperlipidemia were defned using Y10 data and measured in all available CAR-DIA participants. Age, race, sex, and smoking status were obtained by self-report. The major lifestyle variables and clinical measurements were reevaluated at the follow-up examinations. Cumulative average alcohol consumption was classifed into four groups based on daily intake measured using a validated questionnaire. Physical activity (PA) was assessed using the interviewer-administered and validated CARDIA PA history questionnaire [\[31](#page-7-15)]. The PA score was calculated in exercise units, which refect the frequency and duration of activity over the previous year. A score of 100 exercise units is approximately equivalent to participation in vigorous activity for 2–3 h/week for 6 months of the year. The cumulative average PA was categorized into quartiles. At baseline, respondents were asked if they had a history of "kidney problems" (yes/no). If yes, respondents were asked to clarify if they had a history of kidney stones, nephritis, pyelonephritis, glomerulonephritis, kidney infection, or other kidney disease (yes/no). In this study, "kidney diseases" represents self-reported history of kidney stones, nephritis, pyelonephritis, glomerulonephritis, kidney infection, or other kidney disease at baseline (yes/no).

#### **Statistical analysis**

Baseline characteristics of study population were described as means (SDs), medians (IQRs), or proportions based on their properties and distributions. Cox proportional hazards models were used to examine intakes of LCω3PUFA, DHA, EPA, or non-fried fsh in relation to incidence of CKD by calculating multivariable-adjusted HRs and 95% confdence intervals. Schoenfeld residual test was performed to check the proportional hazards assumption [[32](#page-7-16)]. Incident CKD was defned at Y10, Y15, Y20, and Y25. Each participant contributed person-time from baseline to the date when incident CKD was determined, censored or the end of the study, whichever came frst.

To reduce measurement errors caused by within-person variation and to best represent the long-term dietary intakes, we used cumulative average nutrient intake from the measurements at Y0, Y7, and Y20 in the main analysis. For example, we related the average LCω3PUFA intake reported at Y0 and Y7 to the new cases identifed at Y10 and Y15; and the average LCω3PUFA intake reported at Y0, Y7, and Y20 to the new cases identifed at Y20 and Y25. To test the robustness of model selection, we replaced "cumulative average model" with "baseline model", and

"most-recent model", respectively [[33,](#page-7-17) [34](#page-7-18)]. In addition, we used a sequential covariate-adjusted strategy in the Cox model. Model 1 (initial model): adjustment for age, sex, race, and study center. Model 2 (fnal model): Model 1 with additional adjustment for BMI, education, current smoker, alcohol consumption, PA, and total energy, and reported kidney diseases. In Model 2, fried fsh consumption was also adjusted when non-fried fsh was examined. To determine whether sex or race was an effect modifier, the interaction of sex or race with the exposures of interest was detected by likelihood-ratio test. We also examined whether baseline fasting glucose, urinary creatinine, and toenail Se and Hg levels would modify the results. In addition, we conducted the following sensitivity analyses based on the fnal model (Model 2). First, we further adjusted for a few potential dietary confounders, including intakes of magnesium, calcium, sodium, potassium, and phosphorous (Model 3a). Second, we additionally adjusted for baseline creatinine and glucose (Model 3b) on top of Model 2. Third, we reperformed model 2 under a reduced sample size at *n* 3690 including only participants with toenail trace element data available (Model 3c). Fourth, we adjusted for Hg, and cadmium (Model 3d), and further added Se (Model 3e) on top of Model 3c. While baseline glucose is included in Model 3b, we also replaced it with: (1) cumulative glucose levels; or (2) baseline diabetes; or (3) incident diabetes; none of the results were substantially changed. We also performed a sensitivity analysis by adding baseline GFR, blood pressure (either baseline or cumulative), and blood pressure lowering medication at time of CKD ascertainment to the model and the results were materially unchanged.

All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina, USA) with nominal signifcance level set as 0.05, and 0.10 for detecting main efect and interaction, respectively.

## **Results**

Baseline characteristics of the study participants are shown in Table [1.](#page-3-0) The average intake of LCω3PUFAs was 0.17 g/ day and the mean age of the participants was 25.0 years. Of the 4133 participants, 53.2% were women and 49.8% were blacks. The mean eGFR was 123.5 mL/min per 1.73  $m<sup>2</sup>$  and the average follow-up time was 22.3 years.

During the 25-year follow-up, 489 incident cases of CKD were identified. Among them, there were 426/24 cases with moderately/severely increased albuminuria, and 56 cases with decreased eGFR. There were 17 cases with both abnormal eGFR and albuminuria (12/5: moderately/ severely increased albuminuria). Table [2](#page-4-0) shows the associations of intake of LCω3PUFA and non-fried fsh with incident CKD. Higher LCω3PUFA intake had a signifcantly

<span id="page-3-0"></span>**Table 1** Baseline characteristics of the study participants: the CAR-DIA Study (1985–2010) (*n*=4133)



*BMI* body mass index, *CARDIA* Coronary Artery Risk Development in Young Adults, *DHA* docosahexaenoic acid, *eGFR* estimated glomerular fltration rate, *EPA* eicosapentaenoic acid, *EU* exercise unit, *IQR* inter-quartile range, *LCω3PUFA* long-chain omega-3 polyunsaturated fatty acids, *SD* standard deviation

lower incidence of CKD [HR=0.73 (0.60–0.89), *P*=0.002] in model 2. Similar inverse associations were observed for EPA (0.76 (0.62, 0.94), *P*=0.010) and DHA (0.72 (0.59, 0.87), *P*<0.001) intake with incident CKD. A marginally signifcant inverse association was found between non-fried fish consumption and incidence of CKD  $[0.86 (0.73, 1.01),$  $P=0.073$ ].

To determine potential effect modifiers for the associations of interest, we conducted stratifed analyses according to several pre-specifed factors (Table [3\)](#page-5-0). The associations between LCω3PUFA and CKD were modifed by sex, but not by race, Se, or Hg levels. The observed inverse associations persisted in females [HR=0.64 (0.48, 0.84), *P*=0.002], but not in males [HR=0.91 (0.71, 1.18), *P*=0.489] with a *P* value of 0.070 for interaction, indicating a suggestive heterogeneity by sex.

To test the robustness of our fndings, several sensitivity analyses were conducted and results were presented in Table [2](#page-4-0) (model 3a–model 3e). The fndings were overall not appreciably changed. In addition, we used midpoint

<span id="page-4-0"></span>**Table 2** Associations of incident CKD by intakes of LCω3PUFA/non-fried fsh: the CARDIA Study (1985–2010) (*n*=4133)

	$LC03$ PUFA <sup>a</sup>		$DHA^a$		EPA <sup>a</sup>		Non-fried fish <sup>a</sup>	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Model $1b$	0.74(0.61, 0.90)	0.002	0.71(0.59, 0.85)	< 0.001	0.78(0.64, 0.96)	0.017	0.86(0.74, 1.01)	0.064
Model $2c$	0.73(0.60, 0.89)	0.002	0.72(0.59, 0.87)	< 0.001	0.76(0.62, 0.94)	0.010	0.86(0.73, 1.01)	0.073
Model $3a^d$	0.72(0.59, 0.88)	0.002	0.71(0.58, 0.86)	< 0.001	0.75(0.61, 0.92)	0.007	0.85(0.72, 0.999)	0.045
Model $3b^e$	0.76(0.62, 0.93)	0.008	0.74(0.61, 0.90)	< 0.001	0.79(0.64, 0.97)	0.022	0.88(0.75, 1.03)	0.112
Model $3ct$	0.74(0.60, 0.91)	0.004	0.70(0.57, 0.86)	< 0.001	0.78(0.63, 0.97)	0.023	0.86(0.73, 1.02)	0.092
Model $3dg$	0.73(0.59, 0.90)	0.003	0.69(0.56, 0.85)	< 0.001	0.77(0.62, 0.96)	0.018	0.86(0.72, 1.02)	0.078
Model $3eh$	0.72(0.58, 0.90)	0.003	0.68(0.56, 0.84)	< 0.001	0.77(0.61, 0.95)	0.017	0.86(0.72, 1.02)	0.077

Data are HR (95% CIs). All models were constructed using the Cox proportional hazard model and the exposures were the cumulative average intake before the event

*BMI* body mass index, *CARDIA* Coronary Artery Risk Development in Young Adults, *CI* confdence interval, *CKD* chronic kidney disease, *DHA* docosahexaenoic acid, *EPA* eicosapentaenoic acid, *HR* hazard ratio, *LCω3PUFA* long-chain omega-3 polyunsaturated fatty acids

<sup>a</sup> Every 1 SD increment for intakes of LC $\omega$ 3PUFA (SD=0.19 g/day), DHA (SD=0.09 g/day), and EPA (SD=0.08 g/day), and every serving/day increment for non-fried fsh consumption

<sup>b</sup>Model 1: adjustment for age (continuous), sex, race (black or white), and study center

c Model 2: model 1 with additional adjustment for BMI (continuous), education (continuous), current smoker (yes or no), alcohol consumption  $(0, 0.1-4.9, 5.0-9.9, 10.0-19.9, or \geq 20$  g/day), physical activity (quartiles), and total energy (quartiles), and personal kidney problems (yes or no). Fried fsh intake (yes or no) was adjusted only in models when the exposure was non-fried fsh intake

d Model 3a: model 2 with additional adjustment for dietary intakes (quartiles) of magnesium, calcium, sodium, potassium, and phosphorous

e Model 3b: model 2 with additional adjustment for baseline creatinine (continuous) and glucose (continuous)

 $<sup>f</sup>$ Model 3c: model 2 under a reduced sample size at  $n = 3690$  with trace elements measured</sup>

g Model 3d: model 3c with additional adjustment for toenail measurements (quartiles) of mercury, and cadmium

hModel 3e: model 3d with additional adjustment for toenail selenium (quartiles)

imputation instead of right-point imputation considering the interval-censored nature of the outcome; the results remained. Moreover, we replaced "cumulative average model" with "baseline model" and "most-recent model" for dietary intake; the main fndings were consistent excepting some results were somewhat attenuated (data not shown).

## **Discussion**

In this 25-year follow-up prospective study, LCω3PUFA intake and non-fried fsh consumption exhibited overall inverse relations with incidence of CKD in young American adults. Findings from this study suggest that non-fried fish consumption may be beneficial with respect to primary prevention of CKD.

To our knowledge, no previous studies have investigated whether there are sex-dependent diferences in the relation between fsh consumption and incidence of CKD. A crosssectional study of 2600 adults aged  $\geq$  50 years reported an association of increased dietary intake of LCω3PUFA and fish with a reduced risk of CKD [[20\]](#page-7-5). A population-based cohort study of 931 adults aged  $\geq$  65 years showed that higher plasma polyunsaturated fatty acid levels at enrollment were associated with a lower risk of developing renal insufficiency during a 3-year follow-up [\[19\]](#page-7-4). Our study strengthens these fndings given that our timeline of 25 years is substantially longer; studies investigating kidney disease outcomes require at least a 5-to-10-year follow-up. Our study adds new evidence that fsh consumption in young adulthood may be benefcial to primary prevention of CKD later in life.

LCω3PUFA can interfere with several stages of renal fbrosis by acting directly on renal cells and modulating several pathophysiological responses [[7\]](#page-6-4), such as apoptosis, infammation, migration, proliferation, and diferentiation [[35,](#page-7-19) [36](#page-7-20)]. In addition, dietary fsh oil may reduce blood pressure [[8\]](#page-6-5) and proteinuria in patients with hypertension through a mechanism mediated by the vasorelaxant response to LCω3PUFA [\[7](#page-6-4)] and by their modulation of transforming growth factor-beta, renin, fbronectin, and nitric oxide synthesis [\[37](#page-7-21), [38](#page-7-22)].

Sex modifed the inverse association between LCω3PUFA intake and incidence of CKD in this study. The underlying mechanisms are unclear. The type and number of transcripts and plasma lipid response were signifcantly diferent between the sexes after LCω3PUFA supplementation [[39](#page-7-23), [40](#page-7-24)]. For example, HDL cholesterol (HDL-C) levels increased signifcantly for females [\[40](#page-7-24), [41](#page-7-25)]. In the present study, the HDL-C level was higher in females (55.59 mg/dL) than that in males (50.16 mg/dL). HDL-C might maintain <span id="page-5-0"></span>**Table 3** Stratifed analysis of associations between intakes of LCω3PUFA/non-fried fsh with incident CKD: the CARDIA Study (1985–2010) (*n*=4133)



Data are HR (95% CIs) except otherwise specifed. All models were constructed using the Cox proportional hazards model with adjustment for the covariates listed in model 2 in Table [2](#page-4-0)

*CARDIA* Coronary Artery Risk Development in Young Adults, *CI* confdence interval, *CKD* chronic kidney disease, *HR* hazard ratio, *LCω3PUFA* long-chain omega-3 polyunsaturated fatty acids, *SD* standard deviation

a Every 0.19 g/day increment (1 SD) for LCω3PUFA intake, and every serving/day increment for non-fried fish consumption

<sup>b</sup>The analyses were conducted with a size-reduced sample  $(n=3690)$  in which trace elements were measured

and improve renal function through inhibition of intra-renal atherosclerosis [[42\]](#page-7-26), inhibiting the accumulation of lipoproteins on the mesangial cells [[43](#page-7-27)], and the antioxidant effect [\[44\]](#page-7-28). In addition, the anti-inflammatory effects of LCω3PUFA may be acting via changes in gene expression by sex in various and multiple pathways [\[39](#page-7-23), [45](#page-7-29)]. Recently, it has been reported that LCω3PUFA interventions might improve insulin resistance in females but not in males [\[46](#page-8-0)]. However, further studies are warranted.

Our study found a potential beneft of non-fried fsh consumption in relation to incidence of CKD after additional adjustment for dietary intakes of calcium, magnesium, phosphorous, potassium, and sodium in Table [3.](#page-5-0) A possible explanation is that these mineral levels, which are important to CKD patients, are strong confounders [[47,](#page-8-1) [48\]](#page-8-2). Fried fsh tends to be made from lean fsh with little LCω3PUFA compared to fatty fsh [[49\]](#page-8-3). More studies are needed to further investigate the health impact of type of fsh consumption. In addition, frying may reduce the LCω3PUFA content and generate trans-fatty acids and/or oxidative factors that could substantially attenuate the benefts of fsh intake [[25,](#page-7-10) [50](#page-8-4)]. A cohort study in American Indians who consumed predominantly fried fsh found no associations between fsh consumption and any measure of nephropathy [[21,](#page-7-6) [29\]](#page-7-30).

Hg and Se concentrations were directly correlated with fish intake [\[51](#page-8-5)]. Epidemiological studies indicate a possible beneft of Se intake on Hg's vascular toxicity which can be a risk factor of CKD [[9](#page-6-6), [16,](#page-7-1) [52\]](#page-8-6). However, they were not found to be efect modifers of the relation between them and CKD events in this study. Additional research is needed to clarify it.

The strengths of our study include a unique 25-year follow-up prospective study involving young adults, in which both EPA and DHA exerted beneficial effects on kidney function, as reported previously [\[20\]](#page-7-5), and we did stratifed analysis according to several pre-specifed factors including sex. In addition, multiple in-depth dietary measurements were performed. Moreover, we used the cumulative average dietary intakes obtained from multiple measurements during the follow-up, which should reduce the random measurement error and provide a more precise estimate of habitual intake than would a single measurement. Furthermore, we distinguished non-fried from fried fsh, and we conducted a number of sensitivity analyses to test the robustness of our fndings. To our knowledge, this is the frst long-term follow-up study of the association between intake of LCω3PUFA and fish with incidence of CKD.

This study had several limitations. First, although we controlled for many potential confounders, the possibility of residual confounding or bias from unknown or unmeasured factors could not be completely excluded due to the observational property of this study. However, research or monitoring all food and chemicals commercially available is not possible nor is it desirable, as many do not pose a risk to ecosystems or humans [[53\]](#page-8-7). Second, we do not have albuminuria information at baseline. However, we measured albuminuria at Y10. Therefore, if CKD occurred in some cases before Y10, they would not be missed. Third, this study adjusted for toenail Hg and Se. Although the advantage of toenails as a long-term exposure biomarker of trace elements such as Hg and Se status has been recognized [\[54](#page-8-8)], one toenail measurement at baseline may not reflect the changes in their status during the entire follow-up period. Since the changes are likely to be non-diferential, the possible association may be attenuated. Fourth, the recent discovery of the apolipoprotein L1 (APOL1) gene variant has helped to explain racial disparities in the progression of CKD between black and white patients [\[55\]](#page-8-9). While we were unable to adjust for the APOL1 variant, we did adjust for race and did not fnd any efect modifcation by race. Finally, the generalizability of our fndings may be limited. All participants were young American adults mainly from four metropolitan areas, and their characteristics may be different from the general population.

In conclusion, our findings indicate that dietary LCω3PUFA intake is inversely associated with CKD incidence. The results add evidence in support of fish consumption, particularly non-fried fsh, among apparently healthy American young adults. Further studies are warranted to confrm our fndings in other populations.

Acknowledgements We thank the investigators and the staff of the CARDIA Study for their valuable contributions.

**Author contribution** The manuscript has been read and approved by all coauthors. All individuals listed as authors have substantially contributed to the manuscript preparation, and no one other than the authors listed has contributed signifcantly to this study. Specifcally, IP, PX, and KH contributed to the conception and design of the study. IP, PX, CLT, PK, KL, and KH contributed to the analysis and interpretation of data. All of the listed authors contributed to drafting of the manuscript and revising it critically for important intellectual content.

**Funding** The Coronary Artery Risk Development in Young Adults Study (CARDIA) is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HSN268201300028C, HHSN268201300029C, and HHSN268200900041C from the National Heart, Lung, and Blood Institute (NHLBI), the Intramural Research Program of the National Institute on Aging (NIA), and an intraagency agreement between NIA and NHLBI (AG0005). This study was partially supported by grants from the NIH (R01HL081572 and R01ES021735, to Ka He). Inwhee Park was supported by Ajou University School of Medicine, the Republic of Korea. The study sponsor had no role in study design, analysis, or interpretation of data.

#### **Compliance with ethical standards**

**Conflict of interest** None of the authors has any confict of interest to declare.

### **References**

- <span id="page-6-0"></span>1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FD (2016) Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS One 11:e0158765
- <span id="page-6-1"></span>2. Levey AS, Coresh J (2012) Chronic kidney disease. Lancet (London, England) 379:165–180
- 3. Saran R, Robinson B, Abbott KC, Agodoa LY, Ayanian J, Bragg-Gresham J, Balkrishnan R, Chen JL, Cope E, Eggers PW, Gillen D, Gipson D, Hailpern SM, Hall YN, Han Y, He K, Herman W, Heung M, Hutton D, Jacobsen SJ, Kalantar-Zadeh K, Kovesdy CP, Li Y, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, Nguyen DV, O'Hare AM, Obi Y, Plattner B, Pisoni R, Port FK, Rao P, Ravel V, Rhee CM, Sakhuja A, Schaubel DE, Selewski DT, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, White S, Woodside K, Hirth RA, Shahinian V (2017) US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 69:A7–A8
- 4. Bruck K, Stel VS, Gambaro G, Hallan S, Volzke H, Arnlov J, Kastarinen M, Guessous I, Vinhas J, Stengel B, Brenner H, Chudek J, Romundstad S, Tomson C, Gonzalez AO, Bello AK, Ferrieres J, Palmieri L, Browne G, Capuano V, Van Biesen W, Zoccali C, Gansevoort R, Navis G, Rothenbacher D, Ferraro PM, Nitsch D, Wanner C, Jager KJ (2016) CKD prevalence varies across the European general population. J Am Soc Nephrol JASN 27:2135–2147
- <span id="page-6-2"></span>5. Jin DC, Yun SR, Lee SW, Han SW, Kim W, Park J (2016) Current characteristics of dialysis therapy in Korea: 2015 registry data focusing on elderly patients. Kidney Res Clin Pract 35:204–211
- <span id="page-6-3"></span>6. Calder PC, Yaqoob P (2009) Omega-3 polyunsaturated fatty acids and human health outcomes. BioFactors (Oxford, England) 35:266–272
- <span id="page-6-4"></span>7. Baggio B, Musacchio E, Priante G (2005) Polyunsaturated fatty acids and renal fbrosis: pathophysiologic link and potential clinical implications. J Nephrol 18:362–367
- <span id="page-6-5"></span>8. He K (2009) Fish, long-chain omega-3 polyunsaturated fatty acids and prevention of cardiovascular disease—eat fsh or take fsh oil supplement? Prog Cardiovasc Dis 52:95–114
- <span id="page-6-6"></span>9. Xun P, Hou N, Daviglus M, Liu K, Morris JS, Shikany JM, Sidney S, Jacobs DR, He K (2011) Fish oil, selenium and mercury in relation to incidence of hypertension: a 20-year follow-up study. J Intern Med 270:175–186
- <span id="page-6-7"></span>10. de Roos B, Mavrommatis Y, Brouwer IA (2009) Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to infammation and coronary heart disease. Br J Pharmacol 158:413–428
- <span id="page-6-8"></span>11. Lee CC, Adler AI (2012) Recent fndings on the efects of marinederived n-3 polyunsaturated fatty acids on urinary albumin excretion and renal function. Curr Atheroscler Rep 14:535–541
- <span id="page-6-9"></span>12. Donadio JV, Grande JP (2004) The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 24:225–243
- <span id="page-6-10"></span>13. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, VITAL Research Group (2019) Marine n-3 fatty acids

and prevention of cardiovascular disease and cancer. N Engl J Med 380:23–32

- 14. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308:1024–1033
- <span id="page-7-0"></span>15. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R, Omega-3 Treatment Trialists' Collaboration (2018) Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of ten trials involving 77917 individuals. JAMA cardiology 3:225–234
- <span id="page-7-1"></span>16. Gribble MO, Karimi R, Feingold BJ, Nyland JF, O'Hara TM, Gladyshev MI, Chen CY (2016) Mercury, selenium and fsh oils in marine food webs and implications for human health. J Mar Biol Assoc UK 96:43–59
- <span id="page-7-2"></span>17. Li YF, Dong Z, Chen C, Li B, Gao Y, Qu L, Wang T, Fu X, Zhao Y, Chai Z (2012) Organic selenium supplementation increases mercury excretion and decreases oxidative damage in long-term mercury-exposed residents from Wanshan, China. Environ Sci Technol 46:11313–11318
- <span id="page-7-3"></span>18. Ralston NV, Blackwell JL 3rd, Raymond LJ (2007) Importance of molar ratios in selenium-dependent protection against methylmercury toxicity. Biol Trace Elem Res 119:255–268
- <span id="page-7-4"></span>19. Lauretani F, Semba RD, Bandinelli S, Miller ER 3rd, Ruggiero C, Cherubini A, Guralnik JM, Ferrucci L (2008) Plasma polyunsaturated fatty acids and the decline of renal function. Clin Chem 54:475–481
- <span id="page-7-5"></span>20. Gopinath B, Harris DC, Flood VM, Burlutsky G, Mitchell P (2011) Consumption of long-chain n-3 PUFA, alpha-linolenic acid and fsh is associated with the prevalence of chronic kidney disease. Br J Nutr 105:1361–1368
- <span id="page-7-6"></span>21. Lee CC, Howard BV, Mete M, Wang H, Jolly S, Adler AI (2012) Association between fsh consumption and nephropathy in American Indians—the Strong Heart Study. J Renal Nutr Off J Council Renal Nutr Natl Kidney Found 22:221–227
- <span id="page-7-7"></span>22. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, Liu K, Savage PJ (1988) CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 41:1105–1116
- <span id="page-7-8"></span>23. McDonald A, Van Horn L, Slattery M, Hilner J, Bragg C, Caan B, Jacobs D Jr, Liu K, Hubert H, Gernhofer N, Betz E, Havlik D (1991) The CARDIA dietary history: development, implementation, and evaluation. J Am Diet Assoc 91:1104–1112
- <span id="page-7-9"></span>24. Liu K, Slattery M, Jacobs D Jr, Cutter G, McDonald A, Van Horn L, Hilner JE, Caan B, Bragg C, Dyer A (1994) A study of the reliability and comparative validity of the cardia dietary history. Ethn Dis 4:15–27
- <span id="page-7-10"></span>25. Echarte M, Zulet MA, Astiasaran I (2001) Oxidation process afecting fatty acids and cholesterol in fried and roasted salmon. J Agric Food Chem 49:5662–5667
- <span id="page-7-11"></span>26. Levey AS, Stevens LA (2010) Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 55:622–627
- <span id="page-7-12"></span>27. Jacobs DR Jr, Murtaugh MA, Stefes M, Yu X, Roseman J, Goetz FC (2002) Gender- and race-specifc determination of albumin excretion rate using albumin-to-creatinine ratio in single, untimed urine specimens: the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol 155:1114–1119
- <span id="page-7-13"></span>28. Yaemsiri S, Hou N, Slining MM, He K (2010) Growth rate of human fngernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol JEADV 24:420–423
- <span id="page-7-30"></span>29. Garland M, Morris JS, Rosner BA, Stampfer MJ, Spate VL, Baskett CJ, Willett WC, Hunter DJ (1993) Toenail trace element

levels as biomarkers: reproducibility over a 6-year period. Cancer Epidemiol Biomark Prevent Publ Am Assoc Cancer Res Cospons Am Soc Prevent Oncol 2:493–497

- <span id="page-7-14"></span>30. Longnecker MP, Stampfer MJ, Morris JS, Spate V, Baskett C, Mason M, Willett WC (1993) A 1-year trial of the efect of high-selenium bread on selenium concentrations in blood and toenails. Am J Clin Nutr 57:408–413
- <span id="page-7-15"></span>31. Pereira MA, FitzerGerald SJ, Gregg EW, Joswiak ML, Ryan WJ, Suminski RR, Utter AC, Zmuda JM (1997) A collection of Physical Activity Questionnaires for health-related research. Med Sci Sports Exerc 29:S1–S205
- <span id="page-7-16"></span>32. Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515–526
- <span id="page-7-17"></span>33. He K, Rimm EB, Merchant A, Rosner BA, Stampfer MJ, Willett WC, Ascherio A (2002) Fish consumption and risk of stroke in men. JAMA 288:3130–3136
- <span id="page-7-18"></span>34. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A (2003) Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. BMJ 327:777–782
- <span id="page-7-19"></span>35. Graber R, Sumida C, Nunez EA (1994) Fatty acids and cell signal transduction. J Lipid Mediat Cell Signal 9:91–116
- <span id="page-7-20"></span>36. Di Marzo V (1995) Arachidonic acid and eicosanoids as targets and efectors in second messenger interactions. Prostaglandins Leukot Essent Fatty Acids 53:239–254
- <span id="page-7-21"></span>37. Miyazaki M, Takemura N, Watanabe S, Hata N, Misawa Y, Okuyama H (2000) Dietary docosahexaenoic acid ameliorates, but rapeseed oil and safflower oil accelerate renal injury in stroke-prone spontaneously hypertensive rats as compared with soybean oil, which is associated with expression for renal transforming growth factor-beta, fbronectin and renin. Biochem Biophys Acta 1483:101–110
- <span id="page-7-22"></span>38. Das UN (2004) Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr 58:195–203
- <span id="page-7-23"></span>39. Rudkowska I, Paradis AM, Thifault E, Julien P, Tchernof A, Couture P, Lemieux S, Barbier O, Vohl MC (2013) Transcriptomic and metabolomic signatures of an n-3 polyunsaturated fatty acids supplementation in a normolipidemic/normocholesterolemic Caucasian population. J Nutr Biochem 24:54–61
- <span id="page-7-24"></span>40. Mueller BA, Talbert BL, Tegeler CH (1989) Comparative efects of omega-3 fatty acids in men and women. Clin Pharm 8:328–329
- <span id="page-7-25"></span>41. Thifault E, Cormier H, Bouchard-Mercier A, Rudkowska I, Paradis AM, Garneau V, Ouellette C, Lemieux S, Couture P, Vohl MC (2013) Efects of age, sex, body mass index and APOE genotype on cardiovascular biomarker response to an n-3 polyunsaturated fatty acid supplementation. J Nutrigenet Nutrigenom 6:73–82
- <span id="page-7-26"></span>42. Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet (London, England) 2:1309–1311
- <span id="page-7-27"></span>43. Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46–53
- <span id="page-7-28"></span>44. Robbesyn F, Auge N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, Salvayre R (2005) High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol 25:1206–1212
- <span id="page-7-29"></span>45. Ishikado A, Nishio Y, Morino K, Ugi S, Kondo H, Makino T, Kashiwagi A, Maegawa H (2010) Low concentration of 4-hydroxy hexenal increases heme oxygenase-1 expression through activation of Nrf2 and antioxidative activity in vascular endothelial cells. Biochem Biophys Res Commun 402:99–104
- <span id="page-8-0"></span>46. Abbott KA, Burrows TL, Thota RN, Acharya S, Garg ML (2016) Do omega-3 PUFAs affect insulin resistance in a sex-specific manner? A systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 104:1470–1484
- <span id="page-8-1"></span>47. Wright JA, Cavanaugh KL (2010) Dietary sodium in chronic kidney disease: a comprehensive approach. Semin Dial 23:415–421
- <span id="page-8-2"></span>48. Jain N, Reilly RF (2014) Efects of dietary interventions on incidence and progression of CKD. Nat Rev Nephrol 10:712–724
- <span id="page-8-3"></span>49. Mozafarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS (2003) Cardiac benefts of fsh consumption may depend on the type of fsh meal consumed: the Cardiovascular Health Study. Circulation 107:1372–1377
- <span id="page-8-4"></span>50. Phang M, Sinclair AJ, Lincz LF, Garg ML (2012) Gender-specifc inhibition of platelet aggregation following omega-3 fatty acid supplementation. Nutr Metab Cardiovasc Dis NMCD 22:109–114
- <span id="page-8-5"></span>51. Bates CJ, Prentice A, Birch MC, Delves HT, Sinclair KA (2006) Blood indices of selenium and mercury, and their correlations

<span id="page-8-6"></span>52. Buettner C (2003) Mercury and the risk of myocardial infarction. N Engl J Med 348:2151–2154 **(author reply 2151–2154)**

96:523–531

- <span id="page-8-7"></span>53. Anna S, Sofa B, Christina R, Magnus B (2016) The dilemma in prioritizing chemicals for environmental analysis: known versus unknown hazards. Environ Sci Process Impacts 18:1042–1049
- <span id="page-8-8"></span>54. He K (2011) Trace elements in nails as biomarkers in clinical research. Eur J Clin Invest 41:98–102
- <span id="page-8-9"></span>55. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ (2013) APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369:2183–2196